Savara Inc. (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $9.1250.

Several analysts have issued reports on SVRA shares. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Finally, William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th.

Savara Trading Down 0.8%

Shares of SVRA opened at $5.02 on Friday. The company has a market capitalization of $1.03 billion, a P/E ratio of -8.96 and a beta of 0.28. Savara has a one year low of $1.89 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a 50-day moving average price of $5.30 and a 200 day moving average price of $5.50.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Sell-side analysts forecast that Savara will post -0.58 EPS for the current fiscal year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Prudential Financial Inc. acquired a new stake in Savara during the second quarter valued at approximately $30,000. BNP Paribas Financial Markets raised its stake in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in Savara during the second quarter valued at approximately $33,000. Russell Investments Group Ltd. raised its position in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Savara during the 3rd quarter worth approximately $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.